Medidata and TransCelerate BioPharma Join on Risk-Based Monitoring Methodology - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Medidata and TransCelerate BioPharma Join on Risk-Based Monitoring Methodology

Source: Applied Clinical Trials

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that it is partnering with TransCelerate BioPharma on a project designed to inform the nonprofit organization’s efforts around risk-based monitoring.

The joint initiative features Medidata's operational data in the Medidata Clinical Cloud™ to provide metrics and analytics around TransCelerate's recommended methodology on RBM and help answer questions posed by the industry regarding the benefits and challenges associated with a risk-based approach to monitoring of clinical trial sites. The analysis will more rigorously assess the relative contribution of source document verification (SDV) to overall clinical data quality.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here